-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Fate Therapeutics announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that it announced its research on natural killer cell (NK cell) therapy FT516, combined with rituximab, to treat patients with relapsed/refractory B-cell lymphoma.
As of March 11, 2021, a total of 11 patients can be used for safety and efficacy assessment
Picture source: reference [1]
In terms of safety, no dose-limiting toxicity was found, no serious adverse events related to FT516 and adverse events above grade 3 related to FT516 were found
Note: The original text has been deleted
Reference materials:
[1] Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting.